NDA 215596 · Takeda Pharms USA
Livtencity
Maribavir · Oral · Cytomegalovirus pUL97 Kinase Inhibitor
NovelBreakthrough therapyPriority reviewOrphanCDER novel approval, Nov 23, 2021: To treat post-transplant cytomegalovirus (CMV) infection/disease that does not respond (with or without genetic mutations that cause resistance) to available antiviral treatment for CMV
Last checked: Nov 19, 2026Latest source record: Nov 21, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Nov 23, 2021
Approved uses
2
Original approval plus efficacy supplements
Registered trials
18
8 Phase 3, 6 recruiting
FAERS reports
2,469
2,128 serious, 536 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 27, 2026.
LIVTENCITY ® is indicated for the treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet [see Use in Specific Populations (8.4) and Clinical Studies (14) ] . LIVTENCITY is a cytomegalovirus (CMV) pUL97 kinase inhibitor indicated for the treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant CMV infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet. ( 1 , 8.4 )
Mechanism: LIVTENCITY is an antiviral drug against human CMV [see Microbiology (12.4) ] .
Therapeutic areas: Oncology · Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 21, 2025 Supplement 7 · Efficacy OrphanLetterLabel
- Nov 23, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLetterLabelReview
1 products under this application
- LIVTENCITY · MARIBAVIR 200MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Maribavir" as an intervention, any sponsor and status, largest first.
- Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant RecipientsPivotal-lookingCompleted
ShireTakeda (TAK)
NCT00411645 · 681 participants · Start Dec 13, 2006 · Primary completion Nov 10, 2008
Drug: maribavir · For: Cytomegalovirus Infections
Sites: Little Rock, Arkansas; Duarte, California; La Jolla, California · 97 sites in all
- A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell TransplantsPivotal-lookingCompleted
ShireTakeda (TAK)
NCT02927067 · 553 participants · Start Apr 14, 2017 · Primary completion Jul 1, 2022
Drug: Maribavir; Valganciclovir · For: Cytomegalovirus (CMV)
Sites: Birmingham, Alabama; Los Angeles, California; Stanford, California · 129 sites in all
ShireTakeda (TAK)
NCT02931539 · 352 participants · Start Dec 22, 2016 · Primary completion Aug 17, 2020
Drug: Maribavir; Ganciclovir and 3 more · For: Cytomegalovirus (CMV)
Sites: Birmingham, Alabama; Tucson, Arizona; Duarte, California · 134 sites in all
- Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant RecipientsPivotal-lookingCompleted
ShireTakeda (TAK)
NCT00497796 · 307 participants · Start Jul 23, 2007 · Primary completion Sep 14, 2009
Drug: maribavir; ganciclovir · For: Cytomegalovirus Infections
Sites: Phoenix, Arizona; La Jolla, California; Los Angeles, California · 55 sites in all
- Comparing the Efficacy of Different Durations of Maribavir Treatment Regimens in Allo-HSCTPivotal-lookingRecruiting
Ruijin HospitalAcademic, hospital or other
NCT07511127 · 218 participants (planned) · Start Feb 28, 2026 · Primary completion Dec 31, 2027
Drug: Maribavir · For: Hematologic Malignancy
Sites: Shanghai, China
- Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant RecipientsPivotal-lookingCompleted
ShireTakeda (TAK)
NCT01611974 · 120 participants · Start Jul 17, 2012 · Primary completion Dec 5, 2014
Drug: Maribavir · For: Cytomegalovirus (CMV)
Sites: Los Angeles, California; Stanford, California; Denver, Colorado · 32 sites in all
- Maribavir for Prevention of CMV After Stem Cell TransplantsPivotal-lookingCompleted
ShireTakeda (TAK)
NCT00223925 · 111 participants · Start Oct 28, 2004 · Primary completion Apr 5, 2006
Drug: Maribavir; Placebo · For: Cytomegalovirus Infection
Sites: Duarte, California; Los Angeles, California; Maywood, Illinois · 13 sites in all
TakedaTakeda (TAK)
NCT05319353 · 80 participants (planned) · Start Nov 13, 2023 · Primary completion Jan 18, 2027
Drug: Maribavir · For: Cytomegalovirus (CMV)
Sites: Wilmington, Delaware; St. Petersburg, Florida; Chicago, Illinois · 53 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death317
- dysgeusia268
- taste disorder229
- hospitalisation223
- off label use206
- cytomegalovirus infection189
- drug ineffective187
- drug resistance184
- fatigue176
- cytomegalovirus infection reactivation156
- product use issue136
- diarrhoea133
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2012 | 1 |
| 2013 | 2 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 12 |
| 2019 | 11 |
| 2020 | 9 |
| 2021 | 17 |
| 2022 | 497 |
| 2023 | 514 |
| 2024 | 563 |
| 2025 | 556 |
| 2026 | 282 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Livtencity (Maribavir)
2024 spending
$52.0M
Beneficiaries
628
2,147 claims
Per beneficiary
$82,778
$215.88 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $381,019 |
| 2022 | $20,226,514 |
| 2023 | $37,459,523 |
| 2024 | $51,984,298 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial.
Avery RK, Alain S, Alexander BD, et al. · Clin Infect Dis 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
- Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients.
Chou S, Alain S, Cervera C, et al. · J Infect Dis 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Treatment for First Cytomegalovirus Infection Post-Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Valganciclovir.
Papanicolaou GA, Avery RK, Cordonnier C, et al. · Clin Infect Dis 2024 · Clinical Trial, Phase III, Multicenter Study
- Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.
Vernooij RW, Michael M, Ladhani M, et al. · Cochrane Database Syst Rev 2024 · Systematic Review, Meta-Analysis
- Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation.
Maertens J, Cordonnier C, Jaksch P, et al. · N Engl J Med 2019 · Clinical Trial, Phase II, Comparative Study
- Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation.
Chen K, Cheng MP, Hammond SP, et al. · Blood Adv 2018 · Research Support, Non-U.S. Gov't, Systematic Review
Sponsor: Takeda
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.